In particular, the prevalence of KRAS mutations is about 30% in non-small cell lung cancer (NSCLC), 30–50% in CRC, 80% in pancreatic adenocarcinoma and 45–54% in extrahepatic cholangiocarcinoma [21]. This evidence concerns the gene KRAS and colorectal carcinoma.